Paul joined the company in 2012 as head of Cellectricon’s Discovery Services and is now responsible for deal-making and business development in his role as CBO. He previously worked at AstraZeneca (AZ) where he held leadership positions at the Departments of Molecular Pharmacology and Neuroscience. At AZ, Paul led teams responsible for target identification/target validation and ion channel and GPCR profiling in LI-LO phase, mainly in chronic pain and neuropsychiatry projects. Prior to joining AZ, Paul was a Postdoctoral Fellow at School of Medicine, University of Pittsburgh, USA, studying neurobiology using electrophysiological methods. He has a PhD in physiology from University of Gothenburg, Sweden.